Olmesartanmedoxomil/Amlodipin Accord (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil, the active ingredient in Olmesartanmedoxomil/Amlodipin Accord, is a angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension and may be prescribed for adults requiring blood pressure control. GNH USA supplies Olmesartanmedoxomil/Amlodipin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartanmedoxomil/Amlodipin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil/amlodipine is a combination antihypertensive that acts on the renin‑angiotensin system and calcium‑channel pathways to lower blood pressure. - Hypertension: helps achieve target blood pressure in adults. - Hypertensive heart disease: reduces cardiac workload. - Chronic kidney disease with hypertension: slows progression of renal impairment. - High‑risk cardiovascular patients: lowers risk of stroke and myocardial infarction. - Elderly patients with isolated systolic hypertension: improves systolic control.

Common Side Effects: - Headache - Peripheral edema - Dizziness - Flushing - Fatigue - Nasal congestion Serious or Rare Side Effects: - Angio‑edema - Severe hypotension - Elevated liver enzymes - Acute kidney injury - Myocardial infarction in susceptible patients - Severe allergic reactions (anaphylaxis)

Patients should be monitored for blood‑pressure response and renal function during therapy. - Adjust dose in renal impairment: reduce if eGFR <30 mL/min/1.73 m². - Avoid in pregnancy: contraindicated due to fetal toxicity. - Monitor electrolytes: watch for hyperkalemia. - Caution with concurrent diuretics: may increase hypotension risk. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: risk of renal impairment and hyperkalemia. - Dual ACE inhibitor/ARB therapy: increased risk of hypotension, hyperkalemia, and renal dysfunction.\nModerate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - Potassium‑sparing diuretics: increase risk of hyperkalemia. - Simvastatin high dose: amlodipine can increase serum levels, raising myopathy risk. - CYP3A4 inhibitors (e.g., itraconazole): may raise amlodipine concentrations. - CYP3A4 inducers (e.g., rifampicin): may reduce amlodipine efficacy.